The mTOR Substrate S6 Kinase 1 (S6K1) Is a Negative Regulator of Axon Regeneration and a Potential Drug Target for Central Nervous System Injury
- 16 June 2017
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 37 (30) , 7079-7095
Abstract
The mammalian target of rapamycin (mTOR) positively regulates axon growth in the mammalian central nervous system (CNS). Although axon regeneration and functional recovery from CNS injuries are typically limited, knockdown or deletion of PTEN, a negative regulator of mTOR, increases mTOR activity and induces robust axon growth and regeneration. It has been suggested that inhibition of S6 kinase 1 (S6K1, gene symbol: RPS6KB1), a prominent mTOR target, would blunt mTOR9s positive effect on axon growth. In contrast to this expectation, we demonstrate that inhibition of S6K1 in CNS neurons promotes neurite outgrowth in vitro by twofold to threefold. Biochemical analysis revealed that an mTOR-dependent induction of PI3K signaling is involved in mediating this effect of S6K1 inhibition. Importantly, treating female mice in vivo with PF-4708671, a selective S6K1 inhibitor, stimulated corticospinal tract regeneration across a dorsal spinal hemisection between the cervical 5 and 6 cord segments (C5/C6), increasing axon counts for at least 3 mm beyond the injury site at 8 weeks after injury. Concomitantly, treatment with PF-4708671 produced significant locomotor recovery. Pharmacological targeting of S6K1 may therefore constitute an attractive strategy for promoting axon regeneration following CNS injury, especially given that S6K1 inhibitors are being assessed in clinical trials for nononcological indications. SIGNIFICANCE STATEMENT Despite mTOR9s well-established function in promoting axon regeneration, the role of its downstream target, S6 kinase 1 (S6K1), has been unclear. We used cellular assays with primary neurons to demonstrate that S6K1 is a negative regulator of neurite outgrowth, and a spinal cord injury model to show that it is a viable pharmacological target for inducing axon regeneration. We provide mechanistic evidence that S6K19s negative feedback to PI3K signaling is involved in axon growth inhibition, and show that phosphorylation of S6K1 is a more appropriate regeneration indicator than is S6 phosphorylation.Keywords
This publication has 59 references indexed in Scilit:
- Endogenous viruses: insights into viral evolution and impact on host biologyNature Reviews Genetics, 2012
- Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of CancerJournal of Medicinal Chemistry, 2011
- Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of CancerJournal of Medicinal Chemistry, 2010
- PTEN deletion enhances the regenerative ability of adult corticospinal neuronsNature Neuroscience, 2010
- Kinase/phosphatase overexpression reveals pathways regulating hippocampal neuron morphologyMolecular Systems Biology, 2010
- CED-10/Rac1 Mediates Axon Guidance by Regulating the Asymmetric Distribution of MIG-10/LamellipodinCurrent Biology, 2008
- Baculovirus-mediated expression, purification, and characterization of a fully activated catalytic kinase domain construct of the 70kDa 40S ribosomal protein S6 kinase-1 αII isoform (S6K1αII)Protein Expression and Purification, 2007
- Reconstitution of Modular PDK1 Functions on Trans-Splicing of the Regulatory PH and Catalytic Kinase DomainsBioconjugate Chemistry, 2007
- Can experiments in nonhuman primates expedite the translation of treatments for spinal cord injury in humans?Nature Medicine, 2007
- Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitiveNature Cell Biology, 2004